Advancements in the Management of Ovarian Cancer - Episode 3

Brief Overview of Frontline Maintenance Therapy for Advanced Ovarian Cancer

,

Panelists discuss how frontline maintenance therapy options for advanced ovarian cancer are influenced by key factors, such as a patient’s HRD status, and when a combination approach with PARP inhibitors and bevacizumab might be preferred over monotherapy.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Biomarker Testing in Advanced Ovarian Cancer
    EP. 2: Role of Genomic Instability Scores in Treatment Selection
    Now Viewing
    EP. 3: Brief Overview of Frontline Maintenance Therapy for Advanced Ovarian Cancer
    EP. 4: Optimizing PARP Inhibitor Duration
    EP. 5: Overview of PRIMA - Niraparib 1L Maintenance
    EP. 6: Emerging Maintenance Strategies in Advanced/Metastatic Disease: Insights on Combination Therapies and Overcoming PARP Inhibitor Resistance
    EP. 7: Adverse Event Management and Emerging Therapies in Ovarian Cancer: PARPi Challenges and the Role of ADCs

    Video content above is prompted by the following:

    1. Dr Chan to ask Dr Herzog: Briefly review frontline maintenance therapy options for advanced ovarian cancer and highlight the key factors that guide your choice between available therapies.
    • How does a patient’s HRD status influence your selection of maintenance therapy?
    • Under what circumstances would you consider a combination approach with PARP inhibitors and bevacizumab vs using monotherapy?
    x